Back to News
Market Impact: 0.3
COSCIENS Acquires Nualtis For $15 Mln; Raises Up To $20 Mln Via Convertible Debentures
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechTechnology & Innovation
COSCIENS Biopharma announced the acquisition of Montreal-based Nualtis Corp., a specialty pharmaceutical technology company focused on proprietary oral thin-film drug-delivery technologies. The transaction expands COSCIENS' drug-delivery technology capabilities, though the article excerpt provides no purchase price, financial terms, or expected earnings impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CSCI0.65
More News
- Anthropic’s S-1 embodies all the contradictions of the AI boom, and the questions about what happens next
- Wall Street sees this chip stock as the big winner from the Anthropic IPO
- This semiconductor stock slid 35% in October. Raymond James sees a buying opportunity
- Artiva halts AlloNK development, cuts 94% of workforce
- Ripple strikes deal with Robinhood to expand its RLUSD digital dollar
- As Anthropic’s IPO approaches, CFO Krishna Rao faces a defining test